Cystic Fibrosis Presenting as Massive Hepatomegaly

1. Fitzsimmon SC . Annual data report of cystic fibrosis foundation patient registry-1996.

2. Scott-Jupp R , Lama M , Tanner MS . Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991;66:698-701.

3. Feigelson J , Anagnostopoulos C , Poquet M , et al. Liver cirrhosis in cystic fibrosis, Therapeutic implication and long-term follow-up. Arch Dis Child. 1993;68:653-657.

4. Duthie A , Doherty DG , Williams C , et al. Genotype analysis for Delta 506, G551D, and R553X mutation in children and young adults with cystic fibrosis and with and without liver disease. Hepatology. 1992;15:660-664.

5. Waters DL , Dorney SFA , Gruca M , et al. Hepatobiliary disease in cystic fibrosis patients with pancreatic sufficiencv. 1995;21:963-969.

6. Colombo C , Apostolo MG , Ferrari M , et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr. 1994; 124: 393-399.

7. Treem WR , Stanley CA . Massive hepatomegalv, steatosis and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics. 1989;83:933-997.

8. Acosta D , Wenzel DG . Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells. Atherosclerosis. 1974;20:417-426.

9. Wilroy Jr RS , Crawford SE , Johnson WW . Cystic fibrosis with extensive fat replacement of the lix7er. J Pediatr. 1966;68:67-73.

10. Colombo C , Battezzati PM , Podda P , et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. Hepatolo,gy. 1996;23:1484-1490.